Browse the evidence

Semaglutide treatment resulted in a 17% reduction in new-onset atrial fibrillation (AF) incidence compared to controls.

Semaglutide may be an effective treatment option for reducing the risk of new-onset AF in patients.

In trials without SGLT2 inhibitors, there was a significant reduction of 21% in new-onset AF.

Semaglutide may be more effective in reducing AF risk when not used with SGLT2 inhibitors.

Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.

Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

GLP-1 receptor agonists and co-agonists were associated with a lower risk of incident atrial fibrillation among individuals with overweight or obesity.

Practitioners may consider GLP-1RAs and co-agonists as potential options for reducing atrial fibrillation risk in overweight or obese patients.

Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).

Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.

Tirzepatide was more efficacious in younger, male patients of White ethnicity.

Treatment strategies may need to be tailored based on demographic factors for optimal outcomes.

Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).

Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.

Incretin-based therapies were associated with a mean reduction in the apnea-hypopnea index (AHI) of -14.45 events/h.

Incretin-based therapies may effectively reduce AHI in OSA patients, improving sleep quality.

Incretin-based therapies showed a greater effect on AHI compared to usual care, with a mean difference of -11.61 events/h.

Incretin-based therapies may be more effective than usual care for improving AHI in OSA patients.

GLP-1RA use in MUHO is associated with a lower risk of ischemic stroke (HR 0.921) compared to non-use.

GLP-1RAs may be beneficial for reducing ischemic stroke risk in MUHO patients.

Patients with metabolically healthy obesity (MHO) have a markedly lower risk of clinical events compared to those with metabolically unhealthy obesity (MUHO).

Understanding the risk differences can guide treatment decisions for obesity management.

The combination of long-acting PYY analogs with a GLP-1 receptor agonist resulted in superior blood glucose lowering and greater body weight loss compared to GLP-1 alone.

Suggests a potential strategy for enhanced diabetes and obesity treatment.

Semaglutide treatment following catheter ablation for atrial fibrillation is associated with a lower rate of atrial arrhythmia recurrence over 12 months (hazard ratio, 0.68; P =0.030).

Practitioners may consider semaglutide as a therapeutic option to reduce atrial arrhythmia recurrence post-ablation.

In men, a 14.4% ILI-associated increase in total testosterone at year 1 mediated increases in weight (189 g; 95% CI, 65-317) and waist circumference (0.135 cm; 95% CI, 0.19-0.248) at year 4.

Practitioners should consider the role of testosterone in managing weight and waist circumference in men with type 2 diabetes.

In women, a 21.8% decrease in bioavailable testosterone at year 1 mediated decreases in whole-body fat mass (-164; 95% CI, -326 to -29.3), whole-body lean mass (-115 g; 95% CI, -203.4 to -40), and trunk lean mass (-97.2 g; 95% CI, -156 to -45.5) at year 4.

Practitioners should consider the role of bioavailable testosterone in managing body composition in women with type 2 diabetes.

The study revealed sex-specific mediating effects of sex hormones due to weight loss from intensive lifestyle intervention on body composition changes in people with type 2 diabetes.

Practitioners should tailor weight loss recommendations based on sex differences in hormone responses.

49% of patients receiving semaglutide treatment had a full stomach compared to 18% of matched controls.

Clinicians should be aware of the increased risk of full stomach in patients on semaglutide during pre-operative assessments.

Significant improvements were observed across quality-of-life scores.

Incorporating exercise and nutrition can enhance the quality of life for breast cancer patients.

Incretin mimetics have a positive impact on related comorbidities, such as sleep apnea and heart failure.

Practitioners should be aware of the broader health benefits of incretin mimetics beyond glucose control.

Patients may benefit from education on proper drug administration, anticipated adverse effects, and nutrition considerations with treatment.

Educating patients on these aspects can improve treatment adherence and outcomes.

GLP-1 RA therapy improved HBA1C levels from 6.4 to 5.7 (p-value 0.003) in LVAD patients.

GLP-1 RA may help improve glycemic control in LVAD patients.

Dulaglutide showed consistent reductions in HbA1c (1.1%) and weight (1.2 kg).

Dulaglutide is an effective alternative for glycemic control and weight management in T2DM patients.